Neuraxpharm Expands Into The Nordics With New Leader From Viatris
Company Plans To Make Its First Move With Buccolam
In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam.
You may also be interested in...
Privately-owned Neuraxpharm has found another company to give it further access to a new European market, picking up Athens-based Brain Therapeutics. It aims now to introduce its Buccolam (midazolam) in Greece.
Last year was a year of significant executive changes in the off-patent industry, with numerous high-profile hires and departures from companies like Sandoz, Teva, Viatris, Hikma, Fresenius, Neuraxpharm and Stada.
Neuraxpharm has appoints Viatris’ head of finance in Germany as its new commercial central region officer and country manager to strengthen its position in the German market, while Stada has hired a new head of consumer health in Germany. Meanwhile, the AAM has made multiple key appointments and Hyloris, Siegfried and Mayne Pharma have made top-level additions.